Qurin Diagnostics is a biotechnology company that specializes in the early detection of cancer through innovative urine analysis. The company focuses on the development of (epi)genetic urinary biomarkers, which are critical for identifying cancer at its earliest stages. By leveraging nanotechnology and advanced assay development techniques, Qurin aims to create non-invasive diagnostic solutions that are both accurate and user-friendly. Their approach emphasizes the integration of point-of-care urine collection and DNA extraction technologies, allowing for efficient and effective testing that can be easily incorporated into existing laboratory workflows.

The vision of Qurin Diagnostics is to provide diagnostic tests that not only minimize patient discomfort but also empower clinicians to make rapid and informed decisions regarding patient care. By focusing on accessible technologies, Qurin is committed to enhancing the early detection of cancer, ultimately improving patient outcomes. Their innovative methodologies are designed to ensure that diagnostic processes are seamless and engaging, reflecting the company's dedication to advancing cancer diagnostics through cutting-edge science and technology.

Netherlands

Qurin Diagnostics is developing diagnostic technology platform for noninvasive testing. Current developments are focused on advanced biochip technology suitable for multiple biological and biomedical applications.

Qurin Diagnostics

Company Details